Navigation Links
Study measures single-molecule machines in action
Date:7/6/2010

In the development of future molecular devices, new display technologies, and "artificial muscles" in nanoelectromechanical devices, functional molecules are likely to play a primary role.

Rotaxanes, one family of such molecules, are tiny, mechanically interlocked structures that consist of a dumbell-shaped molecule whose rod section is encircled by a ring. These structures behave as molecular "machines," with the ring moving along the rod from one station to another when stimulated by a chemical reaction, light or acidity.

To realize the potential of these molecular machines, however, it is necessary to understand and to measure their function at the nanoscale. Previous methods for observing their operation have involved chemical measurements in solution and studying collections of them attached to surfaces, but neither has provided an accurate picture of their function in environments that are relevant to molecular-device operation.

Now, a multidisciplinary team of researchers from UCLA, Northwestern University, UC Merced, Pennsylvania State University and Japan has succeeded in observing single-molecule interactions of bistable rotaxanes functioning in their native environment.

The team's findings are published in the current edition of the journal ACS Nano.

Led by Paul Weiss from UCLA and Fraser Stoddart from Northwestern University, the team developed a molecular design that firmly attached rotaxanes to a surface, enabling them to be individually examined in their native environment by a scanning tunneling microscope (STM). Using this technology, the researchers were able to record station changes by the rotaxanes' rings along their rods in response to electrochemical signals.

Previously, rotaxanes had to be grouped for study because of their mobility and flexibility when attached to surfaces. And because STM instruments utilize an atomically thin tip to feel out nanoscale surfaces 
'/>"/>

Contact: Mike Rodewald
mrodewald@cnsi.ucla.edu
310-267-5883
University of California - Los Angeles
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources ... will grow at a 12 percent compound annual growth ... of the aging population and the increasing adoption of ... America will also spur demand for dental ... dental implant and periodontal treatments. Other key ...
Breaking Biology Technology:Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... ROTTERDAM, Netherlands, April 24 LyondellBasell Industries today ... voluntarily added to Lyondell Chemical Company,s reorganization filing ... to protect the European holding company against claims ... LyondellBasell Industries AF S.C.A. is a holding company ...
... Maryland have published their assembly of the domestic cow ... the genetics community. The new version of the cow ... both completeness and accuracy. The article describing their research ... Genome Biology . , The research team led ...
... (Nasdaq: KERX ) today announced the appointment of ... Executive Officer, replacing Michael S. Weiss, effective immediately. Mr. ... since September 2007. Mr. Tarnok spent the majority of ... as Finance Director -- US Manufacturing. From 2000-2007, Mr. ...
Cached Biology Technology:LyondellBasell Adds Holding Company to Chapter 11 Protection 2New cow genome sequence released 2Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... N.J., Aug. 14 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... a private placement in which it received $2.8 million ... CEO, stated, "The,proceeds of this financing will help fund ... fourth quarter of this year." At the closing, ...
... Investors Convert Debentures to Equity, JERICHO, N.Y., Aug. ... developer and supplier of consumer,biometric products, today announced that ... Series B common stock warrants that such holders,must surrender ... The Company notified holders of 375,000 series B ...
... in September issue of Nature Methods Shows Application of ... Attachment ... Expression., GENEVA, Switzerland, Aug. 21 Researchers at ... identification of novel,high-performance Genetic Elements also known as matrix ...
Cached Biology News:SyntheMed Completes $2.8 Million Equity Financing 2bioMETRX, Inc. Calls Series B Warrants 2Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines 2
Macrophage-stimulating protein receptor...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Biology Products: